Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma

Kuna, Piotr; Creemers, Jacques; Vondra, Vlastimil; Black, Peter; Lindqvist, Ari; Nihlén, Ulf; Vogelmeier, C. Franz

doi:10.1016/j.rmed.2006.03.016

Cited by 30 publications

(24 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Three trials were included in this comparison [239][240][241] (Table 56). All of them used parallel-group designs and were published between 2001 and 2006.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…Patients receiving BUD only took 400 µg/day. The trial by Kuna and colleagues 241 tested similar regimens, but with higher doses. They compared BUD/FF (80/4.5 µg) at two inhalations once per day (evening), BUD/FF (80/4.5 µg) at one inhalation twice per day (total BUD/FF dose of 160/9 µg/day in both groups) and BUD at 200 µg/day.…”

Section: Study Characteristicsmentioning

confidence: 99%

“…One of the studies included patients who were receiving 'lower dose' ICS (according to the BTS/SIGN Guideline). 1 Patients in the trial by Kuna and colleagues 241 were defined by the authors as having mild to moderate asthma which was not optimally controlled, despite taking 200-500 µg/day of inhaled steroids (unspecified as to which steroid). The other two trials included patients who had been managed on higher doses: 400-1000 µg/day of any corticosteroid in the trial by Buhl and colleagues 240 (patients described by the authors as having moderate persistent suboptimally controlled asthma) and ജ500 µg/day in the trial by Zetterström and colleagues 239 (patients described as having symptomatic asthma despite treatment with ICS).…”

Section: Study Characteristicsmentioning

confidence: 99%

“…2 Only one of the trials specified a primary outcome measure. Kuna and colleagues 241 measured mean change in morning PEF from baseline as their primary outcome. A power calculation is reported for this outcome.…”

Section: Study Characteristicsmentioning

confidence: 99%

See 3 more Smart Citations

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Shepherd¹,

Rogers²,

Anderson³

et al. 2008

Health Technol Assess

View full text Add to dashboard Cite

Non-UK purchasers will have to pay a small fee for post and packing. For European countries the cost is £2 per monograph and for the rest of the world £3 per monograph.You can order HTA monographs from our Despatch Agents:-fax (with credit card or official purchase order) -post (with credit card or official purchase order or cheque) -phone during office hours (credit card only).Additionally the HTA website allows you either to pay securely by credit card or to print out your order and then post or fax it. NHS libraries can subscribe free of charge. Public libraries can subscribe at a very reduced cost of £100 for each volume (normally comprising 30-40 titles). The commercial subscription rate is £300 per volume. Please see our website for details. Subscriptions can only be purchased for the current or forthcoming volume. Contact details are as follows: Payment methods Paying by chequeIf you pay by cheque, the cheque must be in pounds sterling, made payable to Direct Mail Works Ltd and drawn on a bank with a UK address. Paying by credit cardThe following cards are accepted by phone, fax, post or via the website ordering pages: Delta, Eurocard, Mastercard, Solo, Switch and Visa. We advise against sending credit card details in a plain email. Paying by official purchase orderYou can post or fax these, but they must be from public bodies (i.e. NHS or universities) within the UK. We cannot at present accept purchase orders from commercial companies or from outside the UK. How do I get a copy of HTA on CD?Please use the form on the HTA website (www.hta.ac.uk/htacd.htm). Or contact Direct Mail Works (see contact details above) by email, post, fax or phone. HTA on CD is currently free of charge worldwide.The website also provides information about the HTA Programme and lists the membership of the various committees. HTA NIHR Health Technology Assessment ProgrammeT he Health Technology Assessment (HTA) Programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. 'Health technologies' are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care. The research findings from the HTA Programme directly influence decision-making bodies such as the National Institute for Health and Clinical Excellence (NICE) and the National Screening Committee (NSC). HTA findings also help to improve the quality of clinical practice in the NHS indirectly in that they form a key component of the 'National Knowledge Service'. The HTA Programme is needs-led in that it fills gaps in the evidence needed by the NHS. There are three routes to the start of projects. First is the commissioned route. Suggestions for research are actively sought from people working in the NHS, the public and consumer groups and professional bodies such as royal colleges and NHS trusts. These sugges...

show abstract

“…Three trials were included in this comparison [239][240][241] (Table 56). All of them used parallel-group designs and were published between 2001 and 2006.…”

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

Section: Study Characteristicsmentioning

confidence: 99%

See 2 more Smart Citations

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Shepherd¹,

Rogers²,

Anderson³

et al. 2008

Health Technol Assess

View full text Add to dashboard Cite

show abstract

“…Twenty citations were retrieved from the databases, of which 13 did not examine asthma exacerbation or aggravation, and 5 did not examine ICS and FOBA combination therapy. Two articles were identi ed from the reference lists of the retrieved studies, giving a total of 4 RCTs for inclusion in the network meta-analysis 4,6,12,13 .…”

Section: Search Results and Characteristics Of Included Studiesmentioning

confidence: 99%

On-demand Inhaled Corticosteroid and Fast-onset Beta-2 Agonist Combination Therapy Versus Conventional Treatment for Mild to Moderate Asthma: A Non-inferiority, Network Meta-analysis

Andō

Tanaka

Yokoe

et al. 2017

Showa Univ J Med Sci

View full text Add to dashboard Cite

: The aim of this study was to assess the non-inferiority of on-demand OD inhaled corticosteroid ICS and fast-onset beta-2 agonist FOBA combination therapy. Although the guidelines recommend regular inhalation of ICS and long-acting beta-2 agonist LABA , we investigated whether OD-ICS / FOBA is as effective as regular inhalation. A network meta-analysis of randomized controlled trials was conducted to inspect the non-inferiority of OD-ICS / FOBA ef cacy compared with conventional best practice, i.e. regular low-to medium-dose ICS with or without LABA, plus OD short-acting beta-2 agonist REG-ICS OD-SABA or REG-ICS / LABA OD-SABA in patients with mild to moderate asthma. PubMed, the Cochrane library database, and Scopus were searched to identify relevant articles. Outcome measures were the incidence of asthma exacerbation or aggravation. A network meta-analysis was performed to estimate risk ratios RRs with 95 con dence intervals CIs and the probability of being the best treatment for the outcome. Four randomized controlled trials of treatment for mild to moderate asthma met the criteria and were included in the study. We could not demonstrate non-inferiority of OD-ICS / FOBA to REG-ICS OD-SABA RR, 1.17 ; 95 CI, 0.61 to 2.26 or to REG-ICS / LABA OD-SABA RR, 1.47 ; 95 CI, 0.79 to 2.71 for mild to moderate asthma. The probability of being the best treatment to reduce asthma exacerbation or aggravation was 10.5 for OD-ICS / FOBA, 10.3 for REG-ICS OD-SABA, and 79.3 for REG-ICS / LABA OD-SABA. Surface under the cumulative ranking SUCRA curves were 0.4, 0.2 and 0.9 for OD-ICS / FOBA, REG-ICS OD-SABA, and REG-ICS / LABA OD-SABA, respectively. Although non-inferiority of OD-ICS / FOBA to conventional best practice was not shown, SUCRA was higher for OD-ICS / FOBA than for REG-ICS OD-SABA. From these results, we propose that OD-ICS / FOBA can be an effective alternative to REG-ICS OD-SABA to reduce asthma exacerbation or aggravation in patients with mild to moderate asthma.

show abstract

Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children

Ducharme

Chróinín

Greenstone

et al. 2010

Cochrane Database of Systematic Reviews

132

View full text Add to dashboard Cite

Background Long-acting inhaled ß2-adrenergic agonists (LABAs) are recommended as ’add-on’ medication to inhaled corticosteroids (ICS) in the maintenance therapy of asthmatic adults and children aged two years and above. Objectives To quantify in asthmatic patients the safety and efficacy of the addition of LABAs to ICS in patients insufficiently controlled on ICS alone. Search methods We identified randomised controlled trials (RCTs) through electronic database searches (the Cochrane Airways Group Specialised Register, MEDLINE, EMBASE and CINAHL), bibliographies of RCTs and correspondence with manufacturers until May 2008. Selection criteria We included RCTs if they compared the addition of inhaled LABAs versus placebo to the same dose of ICS in children aged two years and above and in adults. Data collection and analysis Two review authors independently assessed studies for methodological quality and extracted data. We obtained confirmation from the trialists when possible. The primary endpoint was the relative risk (RR) of asthma exacerbations requiring rescue oral corticosteroids. Secondary endpoints included pulmonary function tests (PFTs), rescue beta2-agonist use, symptoms, withdrawals and adverse events. Main results Seventy-seven studies met the entry criteria and randomised 21,248 participants (4625 children and 16,623 adults). Participants were generally symptomatic at baseline with moderate airway obstruction despite their current ICS regimen. Formoterol or salmeterol were most frequently added to low-dose ICS (200 to 400 μg/day of beclomethasone (BDP) or equivalent) in 49% of the studies. The addition of a daily LABA to ICS reduced the risk of exacerbations requiring oral steroids by 23% from 15% to 11% (RR 0.77, 95% CI 0.68 to 0.87, 28 studies, 6808 participants). The number needed to treat with the addition of LABA to prevent one use of rescue oral corticosteroids is 41 (29, 72), although the event rates in the ICS groups varied between 0% and 38%. Studies recruiting adults dominated the analysis (6203 adult participants versus 605 children). The subgroup estimate for paediatric studies was not statistically significant (RR 0.89, 95% CI 0.58 to 1.39) and includes the possibility of the superiority of ICS alone in children. Higher than usual dose of LABA was associated with significantly less benefit. The difference in the relative risk of serious adverse events with LABA was not statistically significant from that of ICS alone (RR 1.06, 95% CI 0.87 to 1.30). The addition of LABA led to a significantly greater improvement in FEV1 (0.11 litres, 95% 0.09 to 0.13) and in the proportion of symptom-free days (11.88%, 95% CI 8.25 to 15.50) compared to ICS monotherapy. It was also associated with a reduction in the use of rescue short-acting ß2-agonists (−0.58 puffs/day, 95% CI −0.80 to −0.35), fewer withdrawals due to poor asthma control (RR 0.50, 95% CI 0.41 to 0.61), and fewer withdrawals due to any reason (RR 0.80, 95% CI 0.75 to 0.87). There was no statistically significant group difference ...

show abstract

Once-daily dosing with budesonide/formoterol compared with twice-daily budesonide/formoterol and once-daily budesonide in adults with mild to moderate asthma

Cited by 30 publications

References 30 publications

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

Systematic review and economic analysis of the comparative effectiveness of different inhaled corticosteroids and their usage with long-acting beta2 agonists for the treatment of chronic asthma in adults and children aged 12 years and over

On-demand Inhaled Corticosteroid and Fast-onset Beta-2 Agonist Combination Therapy Versus Conventional Treatment for Mild to Moderate Asthma: A Non-inferiority, Network Meta-analysis

Addition of long-acting beta2-agonists to inhaled corticosteroids versus same dose inhaled corticosteroids for chronic asthma in adults and children

Contact Info

Product

Resources

About